The CRC Digest

Curated CRC research — accessible, accurate, actionable

Saturday, July 11, 2026

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

• ◇ Gut microbes may help microsatellite-stable colorectal cancers respond to immunotherapy

  In mouse models, a Helicobacter-containing microbiome suppressed tumor growth and metastasis by inducing cancer cells to express MHC class II molecules, converting immune-resistant tumors into a more responsive state. (bioRxiv, preprint)

• ◇ Metastatic and non-metastatic colorectal tumors trigger distinct early immune responses

  Using organoid transplant models with T cell fate-mapping, researchers found non-metastatic tumors recruited activated CD8+ and CD4+ T cells with cytotoxic programs, while pro-metastatic tumors induced a naïve-like, hypoactivated T cell state. (bioRxiv, preprint)

• ▪ Novel blood biomarker Ca10H predicts better survival in colorectal cancer

  In a study of 448 individuals, plasma Ca10H levels were significantly higher in CRC patients who survived compared to those who died during follow-up, and were elevated in patients with adenomas, showing an inverse association with tumor progression. (Scientific Reports)

• ♥ Oral sulfate tablets match PEG for colonoscopy prep with improved patient experience

  A randomized trial of adult outpatients found oral sulfate tablets were non-inferior to polyethylene glycol formulations for bowel cleansing, with explicit consideration of patient satisfaction—important since bowel prep is cited as the leading deterrent to elective colonoscopy. (Journal of Clinical Gastroenterology)

Research continues to advance our understanding of how the immune system and microbiome interact with colorectal cancer, while practical improvements in screening and supportive care help patients navigate diagnosis and treatment.

Editorial note: one or more studies referenced above are preprints and have not yet been peer-reviewed; findings are preliminary and may change before formal publication.